Azitra, Inc. (AZTR)
USD 0.28
(-2.52%)
USD 0.28
(-2.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -11.28 Million USD | -5.65% |
| 2022 | -10.68 Million USD | -19.47% |
| 2021 | -8.93 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.63 Million USD | 10.26% |
| 2024 Q1 | -2.93 Million USD | -19.52% |
| 2023 Q3 | -1.94 Million USD | 56.13% |
| 2023 Q1 | -2.45 Million USD | 39.28% |
| 2023 FY | -11.28 Million USD | -5.65% |
| 2023 Q2 | -4.42 Million USD | -80.27% |
| 2023 Q4 | -2.45 Million USD | -26.27% |
| 2022 Q1 | -2.32 Million USD | 0.0% |
| 2022 FY | -10.68 Million USD | -19.47% |
| 2022 Q4 | -4.04 Million USD | -67.38% |
| 2022 Q2 | -1.89 Million USD | 18.74% |
| 2022 Q3 | -2.41 Million USD | -27.91% |
| 2021 FY | -8.93 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 61.039% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -30.72% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 83.657% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 76.886% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -47.81% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -52.88% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 61.378% |
| CEL-SCI Corporation | -32.36 Million USD | 65.137% |
| iBio, Inc. | -24.9 Million USD | 54.696% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 47.483% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 42.933% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 50.816% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 25.653% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -17.052% |
| NanoViricides, Inc. | -8.29 Million USD | -36.045% |
| Oragenics, Inc. | -20.65 Million USD | 45.372% |
| BiomX Inc. | -26.16 Million USD | 56.881% |
| BiomX Inc. | -26.16 Million USD | 56.881% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 235.753% |
| Palatin Technologies, Inc. | -29.73 Million USD | 62.054% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 75.045% |
| Theriva Biologics, Inc. | -18.34 Million USD | 38.505% |